Another theory involves inhibition of angiogenesis supported by in vitro studies demonstrating reduced angiogenesis after zoledronic acid exposure and decreased levels of vascular endothelial growth factor (VEGF) in cancer patients treated with zoledronic acid. Here, VEGFA is linked to cancer.